Verastem, Inc. (2VSA.F)
EUR 4.26
(0.47%)
EUR 4.26
(0.47%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 75.53 Million USD | 19.02% |
| 2021 | 63.46 Million USD | -39.06% |
| 2020 | 104.13 Million USD | -29.16% |
| 2019 | 146.99 Million USD | 21.14% |
| 2018 | 121.33 Million USD | 78.95% |
| 2017 | 67.8 Million USD | 83.24% |
| 2016 | 37 Million USD | -36.42% |
| 2015 | 58.19 Million USD | 8.57% |
| 2014 | 53.6 Million USD | 29.48% |
| 2013 | 41.4 Million USD | 28.46% |
| 2012 | 32.23 Million USD | 135.29% |
| 2011 | 13.69 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 28.27 Million USD | 0.78% |
| 2024 Q1 | 28.05 Million USD | -9.89% |
| 2023 Q3 | 21.3 Million USD | 5.01% |
| 2023 Q2 | 20.29 Million USD | 4.9% |
| 2023 Q1 | 19.34 Million USD | 14.83% |
| 2023 Q4 | 31.13 Million USD | 46.13% |
| 2022 Q1 | 19.57 Million USD | 14.77% |
| 2022 Q4 | 16.84 Million USD | -4.87% |
| 2022 Q3 | 17.7 Million USD | -17.26% |
| 2022 Q2 | 21.4 Million USD | 9.33% |
| 2022 FY | 75.53 Million USD | 19.02% |
| 2021 FY | 63.46 Million USD | -39.06% |
| 2021 Q2 | 16.44 Million USD | 8.8% |
| 2021 Q3 | 14.84 Million USD | -9.71% |
| 2021 Q4 | 17.05 Million USD | 14.87% |
| 2021 Q1 | 15.11 Million USD | -12.37% |
| 2020 Q3 | 31.56 Million USD | 27.37% |
| 2020 Q4 | 17.24 Million USD | -45.36% |
| 2020 Q2 | 24.78 Million USD | -18.81% |
| 2020 Q1 | 30.52 Million USD | -15.63% |
| 2020 FY | 104.13 Million USD | -29.16% |
| 2019 Q1 | 36.18 Million USD | 2.35% |
| 2019 Q2 | 40.64 Million USD | 12.33% |
| 2019 Q3 | 34.37 Million USD | -15.43% |
| 2019 FY | 146.99 Million USD | 21.14% |
| 2019 Q4 | 36.18 Million USD | 5.27% |
| 2018 FY | 121.33 Million USD | 78.95% |
| 2018 Q4 | 35.35 Million USD | -4.52% |
| 2018 Q2 | 28.19 Million USD | 35.8% |
| 2018 Q3 | 37.02 Million USD | 31.33% |
| 2018 Q1 | 20.76 Million USD | 15.01% |
| 2017 Q4 | 18.05 Million USD | -21.98% |
| 2017 FY | 67.8 Million USD | 83.24% |
| 2017 Q3 | 23.13 Million USD | 71.81% |
| 2017 Q2 | 13.46 Million USD | 2.43% |
| 2017 Q1 | 13.14 Million USD | 11.42% |
| 2016 Q4 | 11.8 Million USD | 46.42% |
| 2016 Q3 | 8.05 Million USD | -7.46% |
| 2016 Q1 | 8.43 Million USD | -29.49% |
| 2016 Q2 | 8.7 Million USD | 3.26% |
| 2016 FY | 37 Million USD | -36.42% |
| 2015 Q3 | 15.53 Million USD | 0.47% |
| 2015 Q4 | 11.96 Million USD | -23.0% |
| 2015 Q2 | 15.46 Million USD | 1.44% |
| 2015 Q1 | 15.24 Million USD | 8.89% |
| 2015 FY | 58.19 Million USD | 8.57% |
| 2014 Q3 | 13.38 Million USD | 2.3% |
| 2014 Q4 | 13.99 Million USD | 4.56% |
| 2014 Q1 | 13.13 Million USD | 15.28% |
| 2014 Q2 | 13.08 Million USD | -0.36% |
| 2014 FY | 53.6 Million USD | 29.48% |
| 2013 Q2 | 10.28 Million USD | 13.25% |
| 2013 Q1 | 9.08 Million USD | 13.85% |
| 2013 FY | 41.4 Million USD | 28.46% |
| 2013 Q4 | 11.39 Million USD | 7.04% |
| 2013 Q3 | 10.64 Million USD | 3.5% |
| 2012 Q1 | 6.92 Million USD | 15.08% |
| 2012 Q2 | 6.89 Million USD | -0.46% |
| 2012 Q3 | 10.43 Million USD | 51.25% |
| 2012 FY | 32.23 Million USD | 135.29% |
| 2012 Q4 | 7.97 Million USD | -23.53% |
| 2011 Q4 | 6.02 Million USD | 48.75% |
| 2011 Q3 | 4.04 Million USD | 62.86% |
| 2011 FY | 13.69 Million USD | 0.0% |
| 2011 Q2 | 2.48 Million USD | 116.84% |
| 2011 Q1 | 1.14 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioNTech SE | 2.52 Billion EUR | 97.013% |
| CureVac N.V. | 211.75 Million EUR | 64.33% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 44.786% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 44.786% |
| BRAIN Biotech AG | 24.94 Million EUR | -202.847% |
| Formycon AG | 23.73 Million EUR | -218.261% |
| Heidelberg Pharma AG | 27.81 Million EUR | -171.546% |
| Medigene AG | 20.54 Million EUR | -267.736% |